Strategies for Engineered Negligible Senescence

Last updated

Strategies for Engineered Negligible Senescence (SENS) is a range of proposed regenerative medical therapies, either planned or currently in development, for the periodical repair of all age-related damage to human tissue. These therapies are being developed with the ultimate aim of maintaining a state of negligible senescence in the patient and postponing age-associated disease. [1] SENS was first defined by British biogerontologist Aubrey de Grey.

Contents

While some biogerontologists support the SENS program, many contend that the ultimate goals of de Grey's programme are too speculative given the current state of technology and refer to it as "fantasy rather than science". [2] [3]

Framework

The arrows with flat heads are a notation meaning "inhibits," used in the literature of gene expression and gene regulation. Aging treatment approaches.jpg
The arrows with flat heads are a notation meaning "inhibits," used in the literature of gene expression and gene regulation.

The term "negligible senescence" was first used in the early 1990s by professor Caleb Finch to describe organisms such as lobsters and hydras, which do not show symptoms of aging. The term "engineered negligible senescence" first appeared in print in Aubrey de Grey's 1999 book The Mitochondrial Free Radical Theory of Aging. [4] De Grey defined SENS as a "goal-directed rather than curiosity-driven" [5] approach to the science of aging, and "an effort to expand regenerative medicine into the territory of aging". [6]

The ultimate objective of SENS is the eventual elimination of age-related diseases and infirmity by repeatedly reducing the state of senescence in the organism. The SENS project consists in implementing a series of periodic medical interventions designed to repair, prevent or render irrelevant all the types of molecular and cellular damage that cause age-related pathology and degeneration, in order to avoid debilitation and death from age-related causes. [1]

The Strategies

As described by SENS, the following table details major ailments and the program's proposed preventative strategies: [7]

IssueProposed countermeasures
Extracellular aggregates Immunotherapeutic clearance
Accumulation of senescent cells Senescence marker-targeted toxins, Immunotherapy
Extracellular matrix stiffeningAGE-breaking molecules,tissue engineering
Intracellular aggregatesNovel lysosomal hydrolases
Mitochondrial mutations Allotopic expression of 13 proteins
Cancerous cellsRemoval of telomere-lengthening machinery
Cell loss, tissue atrophyStem cells and tissue engineering

Scientific reception

While some fields mentioned as branches of SENS are supported by the medical research community, e.g., stem cell research, anti-Alzheimers research and oncogenomics, the SENS programme as a whole has been a highly controversial proposal. Many of its critics argue that the SENS agenda is fanciful and that the complicated biomedical phenomena involved in aging contain too many unknowns for SENS to be fully implementable in the foreseeable future. [8]

Cancer may deserve special attention as an aging-associated disease, but the SENS claim that nuclear DNA damage only matters for aging because of cancer has been challenged in the literature, [9] as well as by material in the DNA damage theory of aging. More recently, biogerontologist Marios Kyriazis has criticised the clinical applicability of SENS [10] [11] by claiming that such therapies, even if developed in the laboratory, would be practically unusable by the general public. [12] De Grey responded to one such criticism.[ further explanation needed ] [13]

2005 EMBO Reports statement

In November 2005, 28 biogerontologists published a statement of criticism in EMBO Reports , "Science fact and the SENS agenda: what can we reasonably expect from ageing research?," [8] arguing "each one of the specific proposals that comprise the SENS agenda is, at our present stage of ignorance, exceptionally optimistic," [8] and that some of the specific proposals "will take decades of hard work [to be medically integrated], if [they] ever prove to be useful." [8] The researchers argue that while there is "a rationale for thinking that we might eventually learn how to postpone human illnesses to an important degree," [8] increased basic research, rather than the goal-directed approach of SENS, is currently the scientifically appropriate goal.

Technology Review controversy

In February 2005, the MIT Technology Review published an article by Sherwin Nuland, a Clinical Professor of Surgery at Yale University and the author of "How We Die", [14] that drew a skeptical portrait of SENS, at the time de Grey was a computer associate in the Flybase Facility of the Department of Genetics at the University of Cambridge. [15] While Nuland praised de Grey's intellect and rhetoric, he criticized the SENS framework both for oversimplifying "enormously complex biological problems" and for promising relatively near-at-hand solutions to those unsolved problems. [15]

During June 2005, David Gobel, CEO and co-founder of the Methuselah Foundation with de Grey, offered Technology Review $20,000 to fund a prize competition to publicly clarify the viability of the SENS approach. In July 2005, Jason Pontin announced a $20,000 prize, funded 50/50 by Methuselah Foundation and MIT Technology Review. The contest was open to any molecular biologist, with a record of publication in biogerontology, who could prove that the alleged benefits of SENS were "so wrong that it is unworthy of learned debate." [16] Technology Review received five submissions to its challenge. In March 2006, Technology Review announced that it had chosen a panel of judges for the Challenge: Rodney Brooks, Anita Goel, Nathan Myhrvold, Vikram Sheel Kumar, and Craig Venter. [17] Three of the five submissions met the terms of the prize competition. They were published by Technology Review on June 9, 2006. On July 11, 2006, Technology Review published the results of the SENS Challenge. [18]

In the end, no one won the $20,000 prize. The judges felt that no submission met the criterion of the challenge and discredited SENS, although they unanimously agreed that one submission, by Preston Estep and his colleagues, was the most eloquent. Craig Venter succinctly expressed the prevailing opinion: "Estep et al. ... have not demonstrated that SENS is unworthy of discussion, but the proponents of SENS have not made a compelling case for it." [18] Summarizing the judges' deliberations, Pontin wrote in 2006 that SENS is "highly speculative" and that many of its proposals could not be reproduced with current scientific technology. Myhrvold described SENS as belonging to a kind of "antechamber of science" where they wait until technology and scientific knowledge advance to the point where it can be tested. [18] [19] Estep and his coauthors challenged the result of the contest by saying both that the judges had ruled "outside their area of expertise" and had failed to consider de Grey's frequent misrepresentations of the scientific literature. [20]

SENS Research Foundation

The SENS Research Foundation is a non-profit organization co-founded by Michael Kope, Aubrey de Grey, Jeff Hall, Sarah Marr and Kevin Perrott, which is based in California, United States. Its activities include SENS-based research programs and public relations work for the acceptance of and interest in related research.

See also

Related Research Articles

Senescence Deterioration of function with age

Senescence or biologicalaging is the gradual deterioration of functional characteristics. The word senescence can refer either to cellular senescence or to senescence of the whole organism. Organismal senescence involves an increase in death rates and/or a decrease in fecundity with increasing age, at least in the latter part of an organism's life cycle.

Life extension is the concept of extending the human lifespan, either modestly through improvements in medicine or dramatically by increasing the maximum lifespan beyond its generally-settled limit of 125 years.

Gerontology Study of the social, psychological and biological aspects of aging

Gerontology is the study of the social, cultural, psychological, cognitive, and biological aspects of aging. The word was coined by Ilya Ilyich Mechnikov in 1903, from the Greek γέρων, geron, "old man" and -λογία, -logia, "study of". The field is distinguished from geriatrics, which is the branch of medicine that specializes in the treatment of existing disease in older adults. Gerontologists include researchers and practitioners in the fields of biology, nursing, medicine, criminology, dentistry, social work, physical and occupational therapy, psychology, psychiatry, sociology, economics, political science, architecture, geography, pharmacy, public health, housing, and anthropology.

Aubrey de Grey English author and biogerontologist

Aubrey David Nicholas Jasper de Grey is an English author and biomedical gerontologist. He is the Chief Science Officer of the SENS Research Foundation and VP of New Technology Discovery at AgeX Therapeutics, Inc. He is editor-in-chief of the academic journal Rejuvenation Research, author of The Mitochondrial Free Radical Theory of Aging (1999) and co-author of Ending Aging (2007). He is known for his view that medical technology may enable human beings alive today not to die from age-related causes. He is also an amateur mathematician who has contributed to the study of the Hadwiger–Nelson problem.

Biogerontology Sub-field of gerontology

Biogerontology is the sub-field of gerontology concerned with the biological aging process, its evolutionary origins, and potential means to intervene in the process. It involves interdisciplinary research on the causes, effects, and mechanisms of biological aging. Biogerontologist Leonard Hayflick has said that the natural average lifespan for a human is around 92 years and, if humans not invent new approaches to treat aging, they will be stuck with this lifespan. James Vaupel has predicted that life expectancy in industrialized countries will reach 100 for children born after the year 2000. Many surveyed biogerontologists have predicted life expectancies of more than three centuries for people born after the year 2100. Other scientists, more controversially, suggest the possibility of unlimited lifespans for those currently living. For example, Aubrey de Grey offers the "tentative timeframe" that with adequate funding of research to develop interventions in aging such as Strategies for Engineered Negligible Senescence, "we have a 50/50 chance of developing technology within about 25 to 30 years from now that will, under reasonable assumptions about the rate of subsequent improvements in that technology, allow us to stop people from dying of aging at any age". The idea of this approach is to use presently available technology to extend lifespans of currently living humans long enough for future technological progress to resolve any remaining aging-related issues. This concept has been referred to as longevity escape velocity.

Biological immortality is a state in which the rate of mortality from senescence is stable or decreasing, thus decoupling it from chronological age. Various unicellular and multicellular species, including some vertebrates, achieve this state either throughout their existence or after living long enough. A biologically immortal living being can still die from means other than senescence, such as through injury, poison, disease, lack of available resources, or changes to environment.

Rejuvenation is a medical discipline focused on the practical reversal of the aging process.

Following is a list of topics related to life extension:

<i>Rejuvenation Research</i> Academic journal

Rejuvenation Research is a bimonthly peer-reviewed scientific journal published by Mary Ann Liebert that covers research on rejuvenation and biogerontology. The journal was established in 1998. From 2004 till now its editor-in-chief is Aubrey de Grey. It is the official journal of the European Society of Preventive, Regenerative and Anti-Aging Medicine as well as PYRAMED: World Federation and World Institute of Preventive & Regenerative Medicine.

The following outline is provided as an overview of and topical guide to life extension:

Preston Estep Biogerontologist

Preston W. Estep III is an American biologist and science and technology advocate. He is a graduate of Cornell University, where he did neuroscience research, and he earned a Ph.D. in Genetics from Harvard University. He did his doctoral research in the laboratory of genomics pioneer Professor George M. Church at Harvard Medical School.

Suresh Rattan Indian biogerontologist

Suresh Rattan is a biogerontologist – a researcher in the field of biology of ageing, biogerontology.

Xenocatabolism is a concept in medical bioremediation that relies upon introducing into the body microbial enzymes that break down pathogenic lysosomal, cytosolic and extracellular aggregates. The term, also called xenohydrolysis, was coined by Aubrey de Grey, building upon the work of others. de Grey posited that there are microbes that feed on substances such as amyloid, cholesterol and other related substances in places that are full of human remains, such as graveyards. This was based on the microbial infallibility hypothesis. He states that "the biomedical approach would be to identify the genetic basis for that capacity, and to put one or two genes into ourselves, thereby enhancing our own ability to break things down, and to thereby get rid of things that we cannot naturally break down". In order to add credibility the concept, de Grey created an experiment using soil from a graveyard and took the bacteria from it. He used lipofuscin, "one of the major things that accumulates indigestibly in the body" – which some of the bacteria broke down, lending credibility to the hypothesis. de Grey presented this theory on May 29, 2007, at the Googleplex Google TechTalks.

Aging-associated diseases Type of disease

An aging-associated disease is a disease that is most often seen with increasing frequency with increasing senescence. Essentially, aging-associated diseases are complications arising from senescence. Age-associated diseases are to be distinguished from the aging process itself because all adult animals age, save for a few rare exceptions, but not all adult animals experience all age-associated diseases. Aging-associated diseases do not refer to age-specific diseases, such as the childhood diseases chicken pox and measles. "Aging-associated disease" is used here to mean "diseases of the elderly". Nor should aging-associated diseases be confused with accelerated aging diseases, all of which are genetic disorders.

The Methuselah Foundation is a non-profit organization with declared mission to 'make 90 the new 50 by 2030' by supporting tissue engineering and regenerative medicine therapies. It was co-founded in 2003 by David Gobel and Aubrey de Grey. Their work includes:

David Gobel American philanthropist, entrepreneur, inventor and futurist

David Gobel is an American philanthropist, entrepreneur, inventor, and futurist. He is co-founder and CEO of the Methuselah Foundation, CEO of the Methuselah Fund, and one of the first to publicly advance the idea of longevity escape velocity, even before this term was formulated.

<i>Ending Aging</i> 2007 book by Aubrey de Grey and Michael Rae

Ending Aging: The Rejuvenation Breakthroughs that Could Reverse Human Aging in Our Lifetime is a 2007 book written by Aubrey de Grey, a biogerontologist, with his research assistant Michael Rae. Ending Aging describes de Grey's proposal for eliminating aging as a cause of debilitation and death in humans, and restoring the body to an indefinitely youthful state, a project plan that he calls the "Strategies for Engineered Negligible Senescence", or "SENS". De Grey argues that defeating aging is feasible, possibly within a few decades, and he outlines steps that can be taken to hasten the development of regenerative medicine treatments for each side of aging.

The anti-aging movement is a social movement devoted to eliminating or reversing aging, or reducing the effects of it. A substantial portion of the attention of the movement is on the possibilities for life extension, but there is also interest in techniques such as cosmetic surgery which ameliorate the effects of aging rather than delay or defeat it.

The societal effects of negligible senescence considers a scenario where negligible senescence is achieved on a societal wide level in humans. There is much controversy about the realistic timeline of such a scenario. The predictions vary in time starting from 2037 till later than the 21st century. The effects of negligible senescence has a profound impact on economy, climate, demographics and impacts social structures. The baseline scenario ceteris paribus of negligible senescence is more population growth while a larger healthier labor force would spur economic growth.

People were always interested how to make their lives longer and healthier in old age. Already the most anсient Egyptian, Indian and Chinese writing books contain reasoning about aging. Ancient Egyptians used garlic in large quantities to extend their lifespan. Hippocrates in his Aphorisms and Aristotle (384 – 322 BC) in On youth and old age expresses their opinions about reasons of old age and gave advices about lifestyle. Medieval Persian physician Ibn Sina, known in the West as Avicenna, summarized achievements earlier generations about this issue. Descriptions of rejuvenation and immortality remedies are often in writing of alchemists. But all those remedies did not allow even alchemists themselves to live longer than 100 years.

References

  1. 1 2 de Grey, Aubrey; Rae, Michael (September 2007). Ending Aging: The Rejuvenation Breakthroughs that Could Reverse Human Aging in Our Lifetime. New York, NY: St. Martin's Press, 416 pp. ISBN   0-312-36706-6.
  2. Warner H; Anderson J; Austad S; et al. (November 2005). "Science fact and the SENS agenda. What can we reasonably expect from ageing research?". EMBO Reports. 6 (11): 1006–8. doi:10.1038/sj.embor.7400555. PMC   1371037 . PMID   16264422.
  3. Holliday R (April 2009). "The extreme arrogance of anti-aging medicine". Biogerontology. 10 (2): 223–8. doi:10.1007/s10522-008-9170-6. PMID   18726707. S2CID   764136.
  4. de Grey, Aubrey (November 2003). The Mitochondrial Free Radical Theory of Aging. Austin, Texas: Landes Bioscience. ISBN   1-58706-155-4.
  5. Bulkes, Nyssa (March 6, 2006). "Anti-aging research breakthroughs may add up to 25 years to life". The Northern Star. Northern Illinois University (DeKalb, USA).
  6. . "Age-Related Diseases: Medicine's Final Adversary?". Huffington Post Healthy Living.
  7. "Intro to SENS Research". SENS Research Foundation. Retrieved 2020-08-18.
  8. 1 2 3 4 5 Warner; et al. (2005). "Science fact and the SENS agenda. What can we reasonably expect from ageing research?". EMBO Reports. 6 (11): 1006–1008. doi:10.1038/sj.embor.7400555. PMC   1371037 . PMID   16264422.
  9. Best, BP (2009). "Nuclear DNA damage as a direct cause of aging" (PDF). Rejuvenation Research. 12 (3): 199–208. CiteSeerX   10.1.1.318.738 . doi:10.1089/rej.2009.0847. PMID   19594328.
  10. Kyriazis M (2014). "The impracticality of biomedical rejuvenation therapies: translational and pharmacological barriers". Rejuvenation Research. 17 (4): 390–6. doi:10.1089/rej.2014.1588. PMC   4142774 . PMID   25072550.
  11. Kyriazis, Marios (2015). "Translating laboratory anti-aging biotechnology into applied clinical practice: Problems and obstacles". World Journal of Translational Medicine. 4 (2): 51–4. doi: 10.5528/wjtm.v4.i2.51 .
  12. Kyriazis M, Apostolides A (2015). "The Fallacy of the Longevity Elixir: Negligible Senescence May be Achieved, but Not by Using Something Physical". Current Aging Science. 8 (3): 227–34. doi:10.2174/1874609808666150702095803. PMID   26135528.
  13. de Grey AD (2014). "The practicality or otherwise of biomedical rejuvenation therapies: a response to Kyriazis". Rejuvenation Research. 17 (4): 397–400. doi:10.1089/rej.2014.1599. PMID   25072964.
  14. Nuland, Sherwin (1994). How We Die: Reflections on Life's Final Chapter. New York: Knopf Random House. ISBN   0-679-41461-4.
  15. 1 2 Nuland, Sherwin (1 February 2005). "Do You Want to Live Forever?". MIT Technology Review. Retrieved 28 April 2021.
  16. Pontin, Jason (July 28, 2005). "The SENS Challenge". Technology Review.
  17. Pontin, Jason (March 14, 2006). "We've picked the judges for our biogerontology prize". Technology Review.
  18. 1 2 3 Pontin, Jason (July 11, 2006). "Is Defeating Aging Only A Dream?". Technology Review.
  19. Garreau, Joel (October 31, 2007). "Invincible Man". Washington Post.
  20. Estep, Preston W. (11 July 2006). "Preston Estep et al. Dissent". MIT Technology Review. Retrieved 28 April 2021.

Further reading